PoMA-10 for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 24 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
PoMA-10 may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed PoMA-10 in detail.
, PoMA-10: a dual-action antiviral disrupting SARS-CoV-2 Spike–ACE2 interaction and protecting lung tissue, Frontiers in Pharmacology, doi:10.3389/fphar.2026.1755268
This study aimed to identify small molecules that inhibit the binding of the SARS-CoV-2 Spike protein to its host receptor, angiotensin-converting enzyme 2 (ACE2), without impairing the enzymatic activity of ACE2. Such inhibitors may support the development of broad-spectrum antivirals and therapeutic strategies for emerging SARS-CoV-2 variants. Through extensive screening using both cell-free and cell-based assays, we identified phenoxy-methylaniline (PoMA) compounds as effective inhibitors of the SARS-CoV-2 Spike-ACE2 interaction. Among these, PoMA-10, featuring trifluoromethoxy and dimethylaniline moieties, exhibited the most potent inhibitory activity while preserving ACE2 enzymatic function. Computational modeling predicted direct binding of PoMA-10 to ACE2, which was corroborated by protein mobility shift assays. This was further substantiated by surface plasmon resonance analysis and molecular dynamics simulations, which confirmed the stable binding of PoMA-10 at an interface-adjacent site on ACE2 and the disruption of SARS-CoV-2 Spike–ACE2 interaction. In Vero cells, PoMA-10 significantly reduced infection by ancestral SARS-CoV-2 and the Delta and Gamma variants. Moreover, PoMA-10 alleviated lung epithelial cell damage and protected against lipopolysaccharide-induced lung injury in vivo . These findings demonstrate that PoMA-10 functions as a dual-action inhibitor blocking viral entry and protecting against lung injury, and highlight its potential as a therapeutic candidate in the management of COVID-19 and related pulmonary complications.